Ann: Director Appointments, page-2

Medical technologies firm Admedus Ltd. (ASX: AHZ, “Admedus” or “the Company” has appointed Lishan Zhang and Dr Yanheng Wu as non-executive directors, representing its major investor Star Bright Holding Ltd.

Ms Zhang is a highly successful businesswoman and entrepreneur with a significant network in China that will greatly benefit Admedus. Ms Zhang is the Chair of Constellation International Group Holdings Ltd., a Hong Kong-based company with multiple interests in the development of new biotechnology assets including vaccines, nanotechnology, biomedical materials and minimally invasive tumour treatments. She is also Vice-Chair at Guangzhou Hearty-Care Biotechnology Ltd. and has leadership experience in the areas of strategy, development and financial oversight.

Dr Wu is the President and Managing Director of Constellation International Group Holdings Ltd. and has a PhD in tumour immunotherapy and nanocarrier technology from The University of Queensland. In 2016, he established Guangzhou Hearty-Care Biotechnology Ltd., a medical technology company that is now owned by Constellation International Group Holdings Ltd.

“I am very excited to welcome both Ms Zhang and Dr Wu to our Board of Directors. As a major investor, Star Bright’s interest is aligned with our shareholders, and they are committed to furthering the commercial and development success of Admedus,” said Admedus CEO Wayne Paterson.

“China is a very important market within our global growth strategy. Both Ms Zhang and Dr Wu bring commercial and scientific experience and networks, which will be of great value.” Constellation International Group Holdings Ltd. is strengthening its capabilities in the research and development of medical technology and commercialising innovative products. The Company plans to build a world-class life science industry complex in Shenzhen. It intends to form a joint venture with Admedus to help resource commercial operations in China and fund clinical development programs.